Publication

Diagram comparing high and low LINC01929 effects on cancer cell immune response.

Oncolinc Therapeutics Research Published in iScience

April 17, 2026

We’re excited to share the publication of our latest research in the journal iScience: “LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target.” The study identifies the long non-coding RNA LINC01929 as a key driver of immune evasion in breast cancer and demonstrates that targeting LINC01929 can enhance T cell-mediated killing of tumor cells. These findings support the potential of lncRNA-targeted therapies to overcome tumor immunosuppression and improve cancer immunotherapy responses.

Read the full publication

Latest from Oncolinc

Oncolinc Research Featured in Bloom Burton’s Canada in Science Spotlight

May 20, 2026

Oncolinc’s recent publication, “LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target,” has been featured in Bloom Burton's Canada in Science - March & April 2026 edition. The publication highlights 10 impactful Canadian scientific advances across biotechnology and healthcare research.

View Bloom Burton feature

Oncolinc Awarded Early-Stage Commercialization Funding from Invest Nova Scotia

April 24, 2026

Oncolinc is pleased to announce that we have been selected as a recipient of the Early Stage Commercialization Fund: 2025–2026 Funded Projects supported by Invest Nova Scotia. We are grateful for the support from Invest Nova Scotia, which plays an important role in advancing innovative, high-impact life science companies within the region. This funding will contribute to advancing our research program and strengthening the path toward clinical translation.

Learn more

Publication

Oncolinc Therapeutics Research Published in iScience

Latest from Oncolinc

Oncolinc Research Featured in Bloom Burton’s Canada in Science Spotlight

Oncolinc Awarded Early-Stage Commercialization Funding from Invest Nova Scotia

This website uses cookies.